The present disclosure is related generally to microfluidic diagnostics and more specifically to miniature biochemical diagnostic devices for the detection of pathogens.
Microfluidic diagnostics have been under development for over 20 years. Commercialization of microfluidic devices has been limited, however, given the significant cost, time and technical challenges associated with moving from a prototype to a product; typically about five years and $25 million are required to move from development to manufacturing. Traditionally, microfluidic devices have been produced using injection molding and assembly processes, which may require tools that are slow and costly to make, and difficult to use. Injection molding also limits the devices to mostly two-dimensional (2D) shapes and flow architectures.
A microfluidic diagnostic device with a three-dimensional (3D) flow architecture that provides advantages over conventional microfluidic devices is described in this disclosure. Also described are a point-of-care diagnostic system and a diagnostic method utilizing the microfluidic diagnostic device, as well as a method of making the microfluidic diagnostic device.
The microfluidic diagnostic device comprises a polymeric body having first and second opposing surfaces and comprising first flow channels in the first opposing surface, second flow channels in the second opposing surface, and connecting flow passages extending through a thickness of the polymeric body to connect the first flow channels to the second flow channels, thereby defining a continuous 3D flow pathway in the polymeric body. The microfluidic diagnostic device also includes a first cover adhered to the first opposing surface to seal the first flow channels, a second cover adhered to the second opposing surface to seal the second flow channels, and one or more access ports in fluid communication with the continuous 3D flow pathway for introducing liquid reagent(s) and/or a sample (e.g., a biological sample) into the polymeric body.
Described herein is a microfluidic diagnostic device or “chip” that includes a three-dimensional (3D) flow architecture that allows for improvements in on-chip mixing, chemical and biological functionality, and a reduced form factor compared to conventional microfluidic devices with 2D flow architectures. The improved microfluidic chip may be part of a point-of-care diagnostic system used to detect pathogens (e.g, viruses, bacteria, fungi, mold, yeasts or other infectious agents) from biological samples or samples collected from the environment. The improved microfluidic chip may also or alternatively be part of a point-of-care diagnostic system used to monitor or diagnose a medical condition (e.g, pregnancy, blood sugar level, or other medical conditions) from biological samples. The disposable or reusable microfluidic device may be fabricated using additive manufacturing methods that allow for a rapid transition from design to production. The inventors have demonstrated the ability to design, fabricate, and test functional microfluidic devices having 3D flow architectures within a time period of 6 to 24 hours.
Referring to
The first and second covers 116a,116b may comprise glass or a polymer that is preferably nonreactive with biological samples and reagents. In some examples, the covers 116a,116b may comprise a polymer, glass, ceramic, metal, and/or composite material. One or both covers 116a,116b may have additional functions or may be combined or integrated with other materials or components to provide additional functionality. For example, one or both covers 116a,116b may be combined with an optical element such as an optical filter or material tailored for fluorescence detection measurements. The integrated optical function could include an optical sensor, an optical filter, or an optical amplifier.
Each of the first and second covers 116a,116b may have a microscale thickness (e.g., 10-100 microns) or a larger thickness (e.g., 0.1-3 mm). Typically, at least one of the first cover 116a and the second cover 116b is optically transparent; optical transparency is important when an optical reader is employed for detection, as discussed further below. One or both of the first and second covers 116a,116b can be opaque, partially transparent, or selectively transparent to certain optical wavelengths. For example, the cover 116,116b can be tailored to permit transmission of optical wavelengths specific to the diagnostic test being performed. In one example, one or both covers 116a,116b may comprise adhesive tape (e.g., transparent adhesive tape) which is readily available commercially and enables easy sealing of the first and second flow channels 112a,112b. While generally necessary for diagnostic use of the microfluidic chip 102, the first and second covers 116a,116b may not be illustrated or visible in all figures.
One or both covers 116a,116b or the polymeric body 104 can have integrated electrical elements such as circuit wiring to permit transmission of electrical signals, an electrical antenna, an electrical sensor, a battery, or a radio for wireless transmission of electrical signals. For example, one or both covers 116a,116b or the polymeric body 104 may be integrated with an electrical sensor such as a resistive sensor, a capacitive sensor, a semiconducting sensor or other sensor with electrical function. The sensor can be tailored to detect the presence of certain chemicals, specific molecules, or biological material.
As will be discussed in more detail below in reference to particular examples, the continuous 3D flow pathway 110 in the polymeric body 104 may include one or more functional structures to facilitate fluid transport, mixing, lysing, amplification, storage and/or detection. These functional structures may include flow channel junction(s) 132, flow channel split(s) or furcation(s) 134, mixing structure(s) 136 (such as mixing chamber(s) 138 and/or mixing channel(s) 140, and/or detection reservoir(s) 142. These functional structures may be formed on the front 106 and/or the back 108 of the chip 102 by some combination of the flow channels 112a,112b and/or the connecting flow passage(s) 114.
Notably, the microfluidic diagnostic chip 102 is not limited to the geometry, size and/or flow architecture shown in
Before going into further detail about the design of the microfluidic diagnostic device 102, a method of implementing point-of-care diagnostics using such a device is described. The method entails providing the microfluidic diagnostic chip 102 according to any embodiment or example in this disclosure and introducing one or more liquid reagents and a sample sequentially or simultaneously into the one or more access ports 118. The sample may be a biological sample taken from one or more organisms, a sample taken from the environment, or a sample taken from other sources such as an indoor surface, an outdoor surface, a supply of food or water, a body or stream of air or water, a device tailored to collect or capture pathogens, or a filter material. The liquid reagent(s) and the sample may be introduced in a predetermined sequence and/or at controlled flow rates, utilizing syringes or pumps to control the flow. Once introduced into the one or more access ports 118, the reagent(s) and sample are delivered to the continuous 3D flow path 110 in the polymeric body 104, where reactions and/or mixing occur and a processed fluid sample is formed and contained. The microfluidic diagnostic chip 102 is then positioned such that an optical detector 160 has line-of-sight access to the processed fluid sample, as shown in
The point-of-care method described herein is capable of analyzing a sample and in some cases providing information about the analysis close to the location where the sample is collected. The method can therefore provide an analysis of a sample in a manner that does not require the sample to be stored or transported to a laboratory, and thus the analysis may be completed more quickly. The point-of-care method may be capable of testing smaller numbers of samples than are typically preferred in a laboratory setting; for example, one or fewer than ten samples may be tested, whereas conventional laboratory equipment is typically configured to analyze ten or more samples in parallel.
As indicated above, the microfluidic device 102 includes one or more access ports 118 for introducing fluids into the polymeric body 104, where each access port 118 is in fluid communication with the continuous 3D flow pathway 110. As used herein, the phrase “X is in fluid communication with Y” means that X and Y are configured such that fluid is free to flow between them. In other words, X and Y are either directly connected to each other, or connected to each other via one or more intermediate structures that do not obstruct fluid flow. The one or more access ports 118 may be integrally formed with the polymeric body 104.
Typically, the access port(s) 118 are disposed on one of the first and second opposing surfaces 104a,104b of the polymeric body 104. In the example of
Each access port 118 may be configured to contain and/or connect to a swab, another microfluidic cartridge, a needle, a syringe, or a tube, which may supply the one or more liquid reagents and/or a sample to the microfluidic device 102. It is also conceivable that the access port(s) 118 may be employed to release or remove fluids from the polymeric body 104, if needed.
The polymeric body 104 comprises a polymer that is preferably non-reactive with biological samples and reagents. Suitable polymers may be thermosetting polymers and may include, for example, polyurethane, acrylates and/or epoxides. Other suitable polymers may be thermoplastic polymers such as polylactic acid (PLA) or acrylonitrile butadiene styrene (ABS). Suitable polymers may also include polymers whose shape or chemistry is formed by means of exposure to radiation such as white light, ultraviolet light, or a laser. Given the amenability of the microfluidic chip 102 to additive manufacturing, such as 3D printing, fused deposition modeling, extrusion-based additive manufacturing, vat photopolymerization, or continuous liquid interface production (CLIP) as described below, the polymeric body 104 may be described as a monolithic polymeric body devoid of any bonds or seams.
Both the first and second opposing surfaces 104a,104b of the polymeric body 104 may be planar, as in the examples described so far, meaning that the opposing surfaces 104a,104b are substantially flat, with the exception of surface indentations associated with the first and second flow channels 112a,112b. More generally speaking, at least one of the first and second opposing surfaces 104a,104b may be planar.
In other examples, one or both of the first and second opposing surfaces 104a,104b, and consequently the polymeric body 104, may include a curve (or bend), such that the polymeric body 104 is curved or bent. For example,
It is also contemplated, in examples in which the thickness of the polymeric body approaches the width and/or length of the device, and/or the polymeric body has a 3D shape different from a rectangular prism, that the chip 102 may comprise more than two first and second opposing surfaces 104a,104b. For example, flow channels may be mounted on six sides of a cube, in which these six surfaces are opposing surfaces. The opposing surfaces may be parallel, orthogonal, or have another angle that defines their relative orientation. For example, the flow channels may be mounted on the four surfaces of a regular pyramid.
As shown in
As indicated above, the continuous 3D flow pathway 110 may include one or more functional structures to facilitate fluid transport, mixing, lysing, amplification, storage and/or detection. For example, referring to the exemplary microfluidic chip 102 shown in
For example,
Notably, this 3D flow architecture leads to improved mixing compared to mixing channels having a traditional 2D flow architecture. Finite element simulations of fluid and analyte distribution within the flow reveal a 15% or more increase in mixing performance when the 3D mixing channel 140 described herein is compared to a 2D serpentine channel having the same flow path length.
Another example of a functional structure is illustrated in
In yet another example,
The detection reservoir(s) 142 can be prepared with biological molecules or primers that target specific pathogens, molecules, or chemicals to be detected. The molecules or primers can be delivered to a specific region of the polymeric body 104 or the cover(s) 116a,116b before or after assembly of the chip 102.
Also described in this disclosure is a point-of-care diagnostic system 100 comprising a microfluidic diagnostic device or chip 102, which may have any of the characteristics, features or configurations described herein, and an optical detector 160 positioned with line of sight access to the first or second opposing surface 104a,104b, or more particularly to the one or more detection reservoirs 142 that contain a processed fluid sample. As illustrated in
As indicated above, the microfluidic chip 102 may be rapidly designed and manufactured. A method of making the microfluidic diagnostic device may comprise a first step of generating a computer-aided design of the polymeric body 104. To generate the computer-aided design, a user may provide various inputs, such as the desired microfluidic function, dimensions of specific features, material type, and flow structures specific to the intended application, into a computer-aided design program. These design inputs and dimensions may be generated automatically by a computer program or may be generated manually by a user. The design inputs may be stored in a database and retrieved for the purpose of manufacturing a microfluidic diagnostic chip. The design inputs and dimensions may be delivered over the internet such a through a web browser. By combining these inputs with simulations, prior results, and/or machine learning methods, the program can output a design for the polymeric body 104.
Once the computer-aided design is available (typically within about two hours), the polymeric body 104 may be constructed via additive manufacturing, such as continuous liquid interface production (CLIP) or extrusion-based 3D printing, which may be followed by a curing step (e.g., with ultraviolet radiation, heat, or a latent curing agent). Construction of the polymeric body 104 may be carried out within about six hours. The manufacturing resolution of additive manufacturing techniques, such as CLIP and 3D printing, may be 50 microns. Referring to
After construction of the polymeric body 104, the first cover 116a may be adhered to the first opposing surface 104a and the second cover 116b may be adhered to the second opposing surface 104b, thereby sealing the continuous 3D flow pathway 110 (e.g., the first and second flow passages 112a,112b) and forming the microfluidic diagnostic device 102. As described above in reference to
The subject matter of the disclosure may also relate to the following aspects:
A first aspect relates to a microfluidic diagnostic device with a three-dimensional (3D) flow architecture, the microfluidic diagnostic device comprising: a polymeric body having first and second opposing surfaces and comprising: first flow channels in the first opposing surface; second flow channels in the second opposing surface; and connecting flow passages extending through a thickness of the polymeric body to connect the first flow channels to the second flow channels, thereby defining a continuous 3D flow pathway in the polymeric body; a first cover adhered to the first opposing surface to seal the first flow channels; a second cover adhered to the second opposing surface to seal the second flow channels; and one or more access ports in fluid communication with the continuous 3D flow pathway for introducing liquid reagent(s) and/or a sample into the polymeric body.
A second aspect relates to the microfluidic diagnostic device of the first aspect, wherein at least one of the first cover and the second cover is optically transparent.
A third aspect relates to the microfluidic diagnostic device of the first or second aspect, wherein at least one of the first and second covers comprises adhesive tape.
A fourth aspect relates to the microfluidic diagnostic device of any preceding aspect, wherein the polymeric body comprises a thermosetting polymer, and wherein the polymeric body is a monolithic polymeric body.
A fifth aspect relates to the microfluidic diagnostic device of any preceding aspect, wherein the polymeric body is fabricated by additive manufacturing.
A sixth aspect relates to the microfluidic diagnostic device of any preceding aspect, wherein the continuous 3D flow pathway in the polymeric body comprises one or more functional structures selected from the group consisting of: flow channel junction(s), flow channel furcation(s), mixing structure(s), and detection reservoir(s).
A seventh aspect relates to the microfluidic diagnostic device of any preceding aspect, wherein the continuous 3D flow pathway contains a total volume in a range from about 10 μL to about 1000 μL.
An eighth aspect relates to the microfluidic diagnostic device of any preceding aspect, wherein the one or more access ports are configured to contain and/or connect to a swab, a microfluidic cartridge, a syringe, a needle, and/or a tube.
A ninth aspect relates to the microfluidic diagnostic device of the eighth aspect, wherein the one or more access ports have a tapered and/or stepped internal diameter.
A tenth aspect relates to the microfluidic diagnostic device of the eighth or ninth aspect, wherein the one or more access ports include threads to couple with a mating connector attached to a tube or syringe.
An eleventh aspect relates to the microfluidic diagnostic device of any preceding aspect, wherein the continuous 3D flow pathway includes a mixing channel comprising: a grouping of the first flow channels, each of the first flow channels in the grouping being a U-shaped first flow channel; a grouping of the second flow channels, each of the second flow channels in the grouping being a U-shaped second flow channel; and a grouping of the connecting flow passages, each of the connecting flow passages in the grouping connecting an end of one of the U-shaped first flow channels to an end of one of the U-shaped second flow channels.
A twelfth aspect relates to the microfluidic diagnostic device of the eleventh aspect, wherein the connecting flow passages in the grouping follow a path orthogonal to the U-shaped first and second flow channels.
A thirteenth aspect relates to the microfluidic diagnostic device of any preceding aspect, wherein the continuous 3D flow pathway includes a mixing chamber comprising: one of the first or second flow channels having a width and a length greater than a depth thereof.
A fourteenth aspect relates to the microfluidic diagnostic device of the thirteenth aspect, wherein an inlet to the mixing chamber comprises an end of one of the connecting flow passages, the one of the connecting flow passages being an upstream flow passage, and wherein an outlet from the mixing chamber comprises an end of another of the connecting flow passages, the another of the connecting flow passages being a downstream flow passage.
A fifteenth aspect relates to the microfluidic diagnostic device of the fourteenth aspect, wherein one or both of the upstream and the downstream flow passages follow a path orthogonal to the mixing chamber.
A sixteenth aspect relates to the microfluidic diagnostic device of any preceding aspect, wherein the continuous 3D flow pathway includes a flow channel furcation in fluid communication with a plurality of detection reservoirs, and wherein fluid introduced into the flow channel furcation is evenly distributed to the detection reservoirs.
A seventeenth aspect relates to the microfluidic diagnostic device of the sixteenth aspect, wherein the detection reservoirs radially surround the flow channel furcation.
An eighteenth aspect relates to the microfluidic diagnostic device of the sixteenth or the seventeenth aspects, wherein an inlet to the flow channel furcation comprises an end of one of the connecting flow passages, the one of the connecting flow passages following a path orthogonal to the detection reservoirs.
A nineteenth aspect relates to the microfluidic diagnostic device of any preceding aspect, wherein one or both of the first and second opposing surfaces are planar.
A twentieth aspect relates to the microfluidic diagnostic device of any preceding aspect, wherein one or both of the first and second opposing surfaces include a curve.
A twenty-first aspect relates to the microfluidic diagnostic device of any preceding aspect being configured for diagnostic use in a centrifuge, wherein the first and second flow channels and/or the connecting flow passages are configured such that centrifugal force directs fluid into and/or avoids specific region(s) of the polymeric body.
A twenty-second aspect relates to the microfluidic diagnostic device of any preceding aspect, wherein the polymeric body includes a bend comprising an angle in a range from about 45° to about 135°.
A twenty-third aspect relates to the microfluidic diagnostic device of any preceding aspect, further comprising an electrical sensor integrated with the polymeric body, the first cover and/or the second cover.
A twenty-fourth aspect relates to a point-of-care system comprising: the microfluidic diagnostic device of any preceding aspect; and an optical detector positioned with line of sight access to the first or second opposing surface.
A twenty-fifth aspect relates to the point-of-care system of the twenty-fourth aspect, wherein the optical detector is configured for use with a smart phone.
A twenty-sixth aspect relates to a diagnostic method comprising: providing the microfluidic diagnostic device of any of the first through twenty-third aspects; introducing one or more liquid reagents and a sample sequentially or simultaneously into the one or more access ports for delivery to the continuous 3D flow path, whereby reactions and/or mixing occur and a processed fluid sample is formed and contained; positioning the microfluidic diagnostic device such that an optical detector has line-of-sight access to the processed fluid sample; and impinging light on the processed fluid sample to carry out optical detection.
A twenty-seventh aspect relates to a method of making the microfluidic diagnostic device of any one of of the first through twenty-third aspects, the method comprising: generating a computer aided design of the polymeric body; constructing the polymeric body via additive manufacturing; and adhering the first cover to the first opposing surface and the second cover to the second opposing surface, thereby sealing the first and second flow passages and forming the microfluidic diagnostic device.
A twenty-eighth aspect relates to the method of the twenty-seventh aspect, wherein the additive manufacturing comprises continuous liquid interface production (CLIP) or 3D printing.
A twenty-ninth aspect relates to the method of the twenty-seventh or twenty-eighth aspect, wherein the polymeric body is constructed with a manufacturing resolution of 50 microns.
A thirtieth aspect relates to the method of any one of the twenty-seventh through the twenty-ninth aspects carried out in six hours or less.
Although the present invention has been described in considerable detail with reference to certain embodiments thereof, other embodiments are possible without departing from the present invention. The spirit and scope of the appended claims should not be limited, therefore, to the description of the preferred embodiments contained herein. All embodiments that come within the meaning of the claims, either literally or by equivalence, are intended to be embraced therein.
Furthermore, the advantages described above are not necessarily the only advantages of the invention, and it is not necessarily expected that all of the described advantages will be achieved with every embodiment of the invention.
The present patent document claims the benefit of priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application No. 63/024,692, which was filed on May 14, 2020, and is hereby incorporated by reference in its entirety.
This invention was made with government support under cooperative agreement #D19AC00012 awarded by the Defense Advanced Research Projects Agency of the U.S. Department of Defense. The government has certain rights in the invention.
Number | Name | Date | Kind |
---|---|---|---|
7909502 | Ehrfeld | Mar 2011 | B2 |
8628729 | Carrilho et al. | Jan 2014 | B2 |
9555382 | Clime et al. | Jan 2017 | B2 |
10203307 | Wang | Feb 2019 | B2 |
11198904 | Cai | Dec 2021 | B2 |
20110028669 | Robotti | Feb 2011 | A1 |
20150258544 | Stern | Sep 2015 | A1 |
Entry |
---|
Tani et al., Chip-Based Bioassay Using Bacterial Sensor Strains Immobilized in Three-Dimensional Microfluidic Network, 2004, Anal. Chem., 76, 6693-6697. (Year: 2004). |
Chan et al., Direct, one-step molding of 3D-printed structures for convenient fabrication of truly 3D PDMS microfluidic chips, 2015, Microfluid Nanofluid, 19, 9-18. (Year: 2015). |
Amin, R. et al., “3D-Printed Microfluidic Devices,” Biofabrication, 8, 022001, (2016), pp. 1-17. |
Anciaux, S. K., 3D Printed Micro Free-Flow Devices, Anal. Chem., 88 (2016) 7675-7682. |
Au, A. K. et al., “3D-printed microfluidic automation,” Lab on a Chip, 15 (2015), pp. 1934-1941. |
Au, A. K. et al., “Mail-order microfluidics: Evaluation of stereolithography for the production of microfluidic devices,” Lab on a Chip, 14 (2014), pp. 1294-1301. |
Baumann, E. et al., “Hemolysis of human erythrocytes with saponin affects the membrane structue,” Acta Histochem, 102 (2000), pp. 21-35. |
Bhargava, K. C. et al., “Discrete Elements for 3D Microfluidics,” PNAS, 111, 42, (2014), pp. 15013-15018. |
Bhattacharjee, N. et al., “The Upcoming 3D-Printing Revolution in Microfluidics,” Lab on a Chip, 16, 10 (2016), pp. 1720-1742. |
Brown, R. B. et al., “Current Techniques for Single-Cell Lysis,” J. Royal. Soc. Interface 5 (2008) pp. 5131-5138. |
Chen, D. et al., “An integrated, self-contained microfluidic cassette for isolation, amplification, and detection of nucleic acids,” Biomed. Mircrodevices, 12 (2010) pp. 705-719. |
Chen, W. et al., “Mobile Platform for Multiplexed Detection and Differentiation of Disease-Specific Nucleic Acid Sequences, Using Microfluidic Loop-Mediated Isothermal Amplification and Smartphone detection,” Analytical Chemistry, 89 (2017), pp. 11219-11226. |
Chen, Y. et al., “Point-of-care and visual detection of P. aeruginosa and its toxin genes by multiple LAMP and lateral flow nucleic acid biosensor,” Biosensors and Bioelectronics, 81 (2016), pp. 317-323. |
Chin, C. D. et al., “Commercialization of Microfluidic Point-of-Care Diagnostic Devices,” Lab on a Chip, 12 (2012), pp. 2118-2134. |
Curtis, K. A. et al., “Rapid detection of HIV-1 by Reverse-Transcription, Loop-Mediated Isothermal Amplification ( RT-LAMP),” Journal of Virological Methods, 151 (2008), pp. 264-270. |
Damhorst, G. L. et al. “Smartphone-Imaged HIV-1 Reverse-Transcription Loop-Mediated Isothermal Amplification (RT-LAMP) on a Chip from Whole Blood,” Engineering, 1, 3 (2015) pp. 324-335. |
Donvito, L. et al., “Experimental Validation of a Simple, Low-Cost, T-Junction Droplet Generator Fabricated Through 3D Printing,” Journal of Micromechanics Microengineering, 25, 035013 (2015), pp. 1-6. |
Dou, M. et al., “A Versatile PDMS/Paper Hybrid Microfluidic Platform for Sensitive Infectious Disease Diagnosis,” Analytical Chemistry, 86 (2014) pp. 7978-7986. |
Ganguli, A. et al., “Hands-free smartphone-based diagnostics for simultaneous detection of Zika, Chikungunya, and Dengue at point-of-care,” Biomed. Microdevices, 19, 73 (2017), pp. 1-13. |
Ganguli, A. et al. “Pixelated Spatial Gene Expression Analysis From Tissue,” Nature Communications, 9, 202 (2018), pp. 1-9. |
Gelber, M. K. et al., “Model-Guided Design and Characterization of a High-Precision 3D Printing Process for Carbohydrate Glass,” Additive Manufacturing, (2018), pp. 38-50. |
Gelber, M. K. et al., “Monolithic Multilayer Microfluidics Via Sacrificial Molding of 3D-printed Isomalt,” Lab on a Chip, 15 (2015), pp. 1763-1741. |
Gibson, I. et al., “Additive manufacturing technologies: 3D printing, rapid prototyping, and direct digital manufacturing,” second edition. Additive Manufacturing Technologies: 3D Printing, Rapid Prototyping, and Direct Digital Manufacturing, Second Edition, Springer, New York (2015), pp. 1-509. |
Glick, C. C. et al., “Rapid Assembly of Multilayer Microfluidic Structures Via 3D-Printed Transfer Molding and Bonding,” Microsystems Nanoengineering, 2, 16063 (2016), pp. 1-9. |
Grösche, M. et al., “Microfluidic Chips for Life Sciences—A Comparison of Low Entry Manufacturing Technologies,” Small, 15, 1901956 (2019), pp. 1-9. |
Hassan, U. et al., “A point-of-care microfluidic biochip for quantification of CD64 expression from whole blood for sepsis stratification,” Nature Communications, 8, 15949 (2017), pp. 1-12. |
Hill, J. et al., “Loop-mediated isothermal amplification assay for rapid detection of common strains of Escherichia coli,” Journal of Clinical Microbiology, 46, 8, (2008), pp. 2800-2804. |
Hwang, K. Y. et al., “Miniaturized bead-beating device to automate full DNA sample preparation processes for Gram-positive bacteria,” Lab on a Chip, 11 (2011) pp. 3649-3655. |
Imperato, P. J. “The Potential of Diagnostics for Improving Community Health in Less Developed Countries,” Journal Community Health, 10, 4 (1985), pp. 201-206. |
Islam, M. S., et al., “A review on macroscale and microscale cell lysis methods,” Micromachines, 8, 83 (2017), pp. 1-27. |
Jain, M. et al., “Novel Index for Micromixing Characterization and Comparative Analysis,” Biomicrofluidics, 4 (2010), pp. 031101-1-031101-8. |
Lee, W. et al., “3D-Printed Micro Fluidic Device for the Detection of Pathogenic Bacteria Using Size-Based Separation in Helical Channel with Trapezoid Cross-Section,” Scientific Reports, 5, 7717 (2015), pp. 1-7. |
Liao, C. H et al., “Survivability and long-term preservation of bacteria in water and in phosphate-buffered saline,” Letters in Applied Microbiology, 37 (2003), pp. 45-50. |
Liu, Y. Z. et al., “Two-Fluid Mixing in a Microchannel,” International Journal of Heat and Fluid Flow, 25 (2004) pp. 986-995. |
Macdonald, N. P. et al., “Comparing Microfluidic Performance of Three-Dimensional (3D) Printing Platforms,” Anal. Chem., 89 ( 2017), pp. 3858-3866. |
Mahalanabis, M., et al., “Cell lysis and DNA extraction of gram-positive and gram-negative bacteria from whole blood in a disposable microfluidic chip,” Lab Chip, 9 (2009), pp. 2811-2817. |
Marentis, T. C. et al., “Microfluidic sonicator for real-time disruption of eukaryotic cells and bacterial spores for DNA analysis,” Ultrasound in Medicine and Biology, 31, 9 (2005), pp. 1265-1277. |
McGregor D. J. et al., “Automated Metrology and Geometric Analysis of Additively Manufactured Lattice Structures,” Additive Manufacturing, 28 (2019) pp. 535-545. |
Morgan, A. J. L. et al. “Simple and Versatile 3D Printed Microfluidics using Fused Filament Fabrication,” PLoS One (Apr. 6, 2016) pp. 1-17. |
Notomi, T. et al., “Loop-Mediated Isothermal Amplification of DNA,” Nucleic Acids Research, 28, 12, (2000) pp. 1-7. |
O'Neill, J., “Tackling Drug-Resistant Infections Globally: Final Report and Recommendations,” Review on Antimicrobial Resistance (2016), pp. 1-84. |
Packard, M et al., “Performance Evaluation of Fast Microfluidic Thermal Lysis of Bacteria for Diagnostic Sample Preparation,” Diagnostics, 3 (2013), pp. 105-116. |
Pantazis, A. K. et al. “3D-printed bioreactors for DNA amplification: application to companion diagnostics,” Sensors and Actuators: B. Chemical, 319, 128161 (2020), pp. 1-8. |
Park, J. et al., Thermal cycling characteristics of a 3D-printed serpentine microchannel for DNA amplification by polymerase chain reaction, Sensors Actuators A, 268 (2017) pp. 183-187. |
Qiu, J. et al., “Rapid Customization of 3D Integrated Microfluidic Chips via Modular Structure-Based Design,” ACS Biomaterials Sci. Eng., 3 (2017), pp. 2606-2616. |
S. Razavi Bazaz et al., “3D Printing of Inertial Microfluidic Devices,” Scientific Reports, 10, 5929 (2015), pp. 1-14. |
Saavedra-Matiz, C. A. et al., “Cost-effective and scalable DNA extraction method from dried blood spots,” Clinical Chemistry, 59, 7 (2013) pp. 1045-1051. |
Schilling, E. A. “Cell lysis and protein extraction in a microfluidic device with detection by a fluorogenic enzyme assay,” Anal. Chem. 74, (2002), pp. 1798-1804. |
Sochol, R. D. et al., “3D Printed Microfluidic Circuitry Via Multijet-Based Additive Manufacturing,” Lab on a Chip, 16 (2016), pp. 668-678. |
Sweet, E. C. et al., “3D Printed Chaotic Mixer for Low Reynolds Number Microfluidics,” 20th International Conference on Solid-State Sensors, Actuators and Microsystems, Berlin, Germany (Jun. 23-27, 2019), pp. 2258-2261. |
Tofteberg, T. et al., “A Novel Passive Micromixer: Lamination in a Planar Channel System,” Microfluid. Nanofluidics, 8 (2010), pp. 209-215. |
Tanner, N. A.et al., “Visual detection of isothermal nucleic acid amplification using pH-sensitive dyes,”. Biotechniques, 58 (2015) pp. 59-68. |
Tumbleston, J. R. et al. “Continuous Liquid Interface Production of 3D Objects,” Science, 347, 6228 (2015), pp. 1349-1352. |
Wolk, D. et al., “Principles of Molecular Microbiology Testing Methods,” Infectious Disease Clinics of North America, 15, 4 (2001), pp. 1157-1204. |
Yager, P. et al. “Point-of-Care Diagnostics for Global Health,” Annu. Rev. Biomed. Eng., 10 (2008) pp. 107-144. |
Number | Date | Country | |
---|---|---|---|
20210354139 A1 | Nov 2021 | US |
Number | Date | Country | |
---|---|---|---|
63024692 | May 2020 | US |